SCLC

[Seminars in Cancer Biology] Scientists summarize the roles of distinct immunogenic cell death mechanisms on antitumor immunity and recent advances of ferroptosis-, necroptosis- and pyroptosis-inducing agents, and present perspectives on these cell death mechanisms in immunotherapy of SCLC.

[Seminars in Cancer Biology] The authors review the advancements in transformed SCLC, including clinical and pathological characteristics, and the potential effective treatment after SCLC transformation, aiming to give a better understanding of transformed SCLC and provide support for clinical uses.

[EMBO Molecular Medicine] Investigators focused on the neuroendocrine SCLC subtypes, SCLC-A and SCLC-N, whose transcription addiction was driven by ASCL1 and NEUROD1 transcription factors which targeted E-box motifs to activate up to 40% of total genes.

[Harpoon Therapeutics, Inc.] Harpoon Therapeutics, Inc. announced that the US FDA has granted Orphan Drug Designation for HPN328, a delta like ligand 3- targeting TriTAC®, for the treatment of SCLC.

[Akeso, Inc. (BioSpace, Inc.)] -Akeso, Inc. announced that it entered into a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd. to establish a clinical trial partnership to jointly conduct a Phase Ib/II clinical trial of PD-1/CTLA-4 bi-specific antibody Cadonilimab in combination with Chiauranib for the treatment of first-line platinum-based chemotherapy in combination with PD-(L)1 inhibitor treatment regimen for extensive stage small cell lung cancer.

[Seminars in Cancer Biology] Scientists review current clinical trials of epigenetic therapy against small cell lung cancer and the mechanisms of epigenetic inhibitors to boost antitumor immunity.